Overview

Copanlisib Mass Balance Study

Status:
Completed

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

Summary

The study aims to provide understanding of the relative relevance of the different excretion pathways of Copanlisib in humans, as well as to characterize its metabolite profile.

Phase:

Phase 1

Details

Lead Sponsor:

Bayer